Hybrid Program | 6.00 CE/CME Credits & MOC Points
All programs remain free. Registrations will require a credit card as a cancellation hold. A fee of $99 will only be incurred in the event of a no-show or cancellation within 5 days without written confirmation to the Total Health Program Team.
The 3rd Annual Best of Hematology Conference is an innovative and state-of-the-art program that features some of the world's leading hematologists presenting the latest research and strategies for the care of hematological malignancies — incorporating data from the major oncologic annual meetings.
Conference Agenda
Saturday, February 7th, 2026
7:30 AM
Coffee and Exhibits
8:00 AM
Welcome and Opening Remarks
8:10 AM
Targeted and MRD-Driven Approaches in Acute Leukemia
Mat Angelos, MD | University of Colorado Cancer Center
8:40 AM
Chronic Leukemia: Targetable Pathways in CLL
Steven Bair, MD | University of Colorado Anschutz
9:10 AM
Breakfast and Exhibits
9:25 AM
Non-CME Breakfast - Regeneron - Explore A Treatment Option For Your Patients With R/R Multiple Myeloma
Cesar Rodriguez, MD | Mount Sinai
10:10 AM
Moving Beyond R-CHOP in DLBCL
Michael Tees, MD, MPH | Colorado Blood Cancer Institute
10:40 AM
Indolent Lymphoma: Strategies for Personalizing Long-Term Care
Ann S. LaCasce, MD | Dana-Farber Cancer Institute
11:10 AM
Lunch and Exhibits
11:35 AM
Non-CME Lunch - Incyte - Thrombotic Risk in Patients With Polycythemia Vera | Identify When to Intervene With Jakafi® (ruxolitinib)
Sepehr Rokhsar, MD | Cedars-Sinai/Tower Hematology Oncology Medical Group
12:20 PM
Extended Panel Discussion: Game-Changing Results from 2025 – What Will Be the Impact on Current Practice?
Ajay Major, MD (Moderator) | University of Colorado Anschutz
Mat Angelos, MD | University of Colorado Cancer Center
Steven Bair, MD |University of Colorado Anschutz
Michael Tees, MD | Colorado Blood Cancer Institute
Ann S. LaCasce, MD | Dana-Farber Cancer Institute
1:20 PM
Adjourn
Sunday, February 8th, 2026
7:30 AM
Coffee and Exhibits
8:00 AM
Welcome and Opening Remarks
8:10 AM
Bispecifics, CAR-T Cells, and Sequencing Strategies in Multiple Myeloma
Jorge Monge, MD | University of Colorado Cancer Center
8:40 AM
What's New in the T-Cell and Rare Lymphomas?
Bradley Haverkos, MD | University of Colorado
9:10 AM
Breakfast and Exhibits
9:25 AM
Non-CME Breakfast - GSK - Advancing Multiple Myeloma Care: The Clinician’s Role in the Safe and Effective Use of Blenrep
Eleni Allen, PharmD, RPh | GSK
Robert Rifkin, MD | UCHealth Jan Bishop Cancer Center - Steamboat Springs
10:10 AM
Myelodysplastic and Myeloproliferative Neoplasms
Samuel Urrutia, MD | Washington University in St. Louis
10:40 AM
Sickle Cell Disease & Thalassemia: Gene Therapy and Novel Approaches
Elizabeth Traxler, MD | Perelman School of Medicine at University of Pennsylvania
11:10 PM
Housekeeping and Survey
11:20 AM
Lunch and Exhibits
11:35 AM
Non-CME Lunch - Pfizer Elrexfio - Advancing Care in RRMM: Clinical Evidence for a BCMA-Directed Bispecific Antibody Treatment Option
Peter Forsberg, MD | Colorado Blood Cancer Institute
12:20 PM
Extended Panel Discussion: How and When Do You Integrate Novel Therapies into Practice?
Erin Schwab, MD (Moderator) | Vail Health
Samuel Urrutia, MD | Washington University in St. Louis
Jorge Monge, MD | University of Colorado Cancer center
Bradley Haverkos, MD | University of Colorado
Elizabeth Traxler, MD | Perelman School of Medicine at University of Pennsylvania
1:20 PM
AJOURN
Agenda Subject To Change. All times are MST.
-
Apply the current standards of oncology care and key updates from national clinical guidance pathways to optimize the management of patients with various hematologic malignancies.
Review new, emerging, and novel therapeutic agents and treatment strategies and incorporate these into the management of patients with hematologic malignancies.
Communicate with members of the interprofessional oncology care team to improve collaborative performance in the management of patients with hematologic malignancies.
-
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by
Amedco LLC and Total Health Conferences. Amedco LLC is jointly accredited by the
Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council
for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to
provide continuing education for the healthcare team.
Professions in scope for this activity are listed below.
Amedco Joint Accreditation Provider Number: 4008163
Physicians
Amedco LLC designates this live activity for a maximum of 6.00 AMA PRA Category 1 CreditsTM for physicians.
Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Pharmacists & Pharmacy Technicians
Amedco LLC designates this activity for a maximum of 6.00 knowledge-based CPE contact hours.
JA4008163-9999-26-050-L01-P | JA4008163-9999-26-050-L01-T
NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request
your certificate within 45 days of your participation in the activity to meet the deadline for submission to CPE Monitor.
Credits are generally reported during the first week of each month for those who claimed during the month prior.
Nurses
Amedco LLC designates this activity for a maximum of 6.00 ANCC contact hours.
American Board of Internal Medicine (ABIM) MOC
Successful completion of this CME activity, which includes participation in the evaluation component,
Learner Notification
enables the participant to earn up to 6.00 Medical Knowledge MOC points in the American Board of
Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to
submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
You must request your certificate within 45 days of the activity to meet the deadline for submission to PARS.
Credits are generally reported during the first week of each month for those who claimed during the month
prior.
Objectives - After Attending This Program You Should Be Able To
1. Review new, emerging, and novel therapeutic agents and treatment strategies and incorporate these into the
management of patients with hematologic malignancies.
2. Apply the current standards of oncology care and key updates from national clinical guidance pathways to optimize
the management of patients with various hematologic malignancies.
3. Communicate with members of the interprofessional oncology care team to improve collaborative performance in the
management of patients with hematologic malignancies
-
Free registration for all healthcare providers
Expert sessions that present the most clinically relevant data, research, and clinical strategies
Real-time discussion and debate
Networking with peers, colleagues, and medical professionals
Access to the latest industry information and resources